DRNA News and Press, Dicerna Pharmaceuticals Inc. From 07/06/21

Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $39.68, eclipsing its 52-week high. Approximately 124,000 shares have changed hands today, as compared to an average 30-day volume of 723,000 shares. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) is currently priced 8.5% a...

Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...

Landscape and nature photographer based in Upstate, New York/iStock Editorial via Getty Images Rite Aid could be a “show-me story” in fiscal 2022: Piper Sandler With a ~14.5% loss in share price, Rite Aid (RAD) market cap fell below $1B yesterday in reaction to the mixed perform...

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $38.50, eclipsing its 52-week high. Approximately 124,000 shares have changed hands today, as compared to an average 30-day volume of 739,000 shares. Dicerna Pharmaceuticals Inc is a biotechnology company involved in th...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced it has initiated patient dosing in the Company’s Phase 2 ESTRELLA trial o...

Dicerna Pharmaceuticals (DRNA) has completed dosing in the company’s PHYOX4 single-dose safety and tolerability study of its investigational candidate, nedosiran, for the treatment of primary hyperoxaluria ((PH)) type 3 ((PH3)).Primary hyperoxaluria ((PH)) is a family of ultra-rar...

– Company Continues to Expect Nedosiran New Drug Application Submission in Fourth Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic aci...

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded at a new 52-week high today of $38.01. This new high was reached on below average trading volume as 124,000 shares traded hands, while the average 30-day volume is approximately 724,000 shares. Dicerna Pharmaceuticals Inc is a b...

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $33.73, eclipsing its 52-week high. This new high was reached on below average trading volume as 124,000 shares traded hands, while the average 30-day volume is approximately 711,000 shares. Dicerna Pharmaceuticals Inc....